{
  "docId": "019de072-afcf-751b-be79-65bbe03fb0c7",
  "docSlug": "a4681640730b4446aa1f6ee077b8a572",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 23 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 23,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/22",
  "deckHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7",
  "deckJsonHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json",
  "deckAnchorHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.88,
        "x": 0.028,
        "y": 0.25
      },
      "kind": "list",
      "text": "IND enabling studies underway; Primate dose range finding study completed; Manufacturing initiated; Pre-IND meeting completed; Phase 1 study planning; Multiple ascending dose dose-escalation study; 5 doses planned: 0.1, 0.3, 1.0, 3.0, and 10 mg/kg; Post PD-1 or PD-L1 patient population; PD-1 shedding on peripheral T cells as a pharmacodynamic marker; IND submission targeted for Q1 2023; Potential for proprietary combination regimens with CTX-009 and CTX-471",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5bc0e5b-1838-4c79-b018-20b4e5af5548",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.515,
        "x": 0.028,
        "y": 0.145
      },
      "kind": "title",
      "text": "CTX-8371: Development Status",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63ca1d2c-7d5c-4003-be65-dc776fe6b414",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 23,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667",
      "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company",
      "position": 0,
      "objective": "Highlight the potential consequences of not investing in Compass Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}